Veramed
Freight & Logistics Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
40 Nagog Park Ste 210, Acton, Massachuse...Website
www.veramed.comRevenue
$49.6 MillionIndustry
About Veramed
Veramed Org Chart
Is Veramed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Veramed had a recent Job posting/layoffs
Check if Veramed has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Veramed has new funding data
Product Launch: Get notified when Veramed launches new products
Earning: See what the market has to say on Veramed recently announced quarterly report
Veramed, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Veramed is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Veramed
Recommended Actions
Find VP level buyers at Veramed
Find 3 more new buyers
Company Profile Activity
Activity Insights
Veramed is experiencing very low activity levels compared to other companies in the Transportation sector.
What does this means?
Veramed is drawing exceptional interest within the Transportation industry, suggesting notable developments or strong market momentum, learn more about Veramed.
Veramed Tech Stack
A closer look at the technologies used by Veramed
Most Recent Scoops
Top Freight & Logistics Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Veramed
Veramed is a specialist biometrics Contract Research Organization (CRO) headquartered in Twickenham, England, with offices across the UK, Europe, the United States, and India. Founded in 2012, the company provides expert data management, biostatistics, and statistical programming services to pharmaceutical and biotech clients supporting Phase IIV c... Read More